JP2021502065A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502065A5 JP2021502065A5 JP2020524144A JP2020524144A JP2021502065A5 JP 2021502065 A5 JP2021502065 A5 JP 2021502065A5 JP 2020524144 A JP2020524144 A JP 2020524144A JP 2020524144 A JP2020524144 A JP 2020524144A JP 2021502065 A5 JP2021502065 A5 JP 2021502065A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 176
- 239000000427 antigen Substances 0.000 claims description 87
- 102000036639 antigens Human genes 0.000 claims description 87
- 108091007433 antigens Proteins 0.000 claims description 87
- 239000012634 fragment Substances 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 29
- 108700041144 Angiopoietin-Like Protein 8 Proteins 0.000 claims description 18
- 102100034604 Angiopoietin-like protein 8 Human genes 0.000 claims description 18
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 17
- 206010014486 Elevated triglycerides Diseases 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 101000924544 Homo sapiens Angiopoietin-like protein 8 Proteins 0.000 claims description 6
- 238000008214 LDL Cholesterol Methods 0.000 claims description 6
- 102000050918 human ANGPTL8 Human genes 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229940125753 fibrate Drugs 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 208000003532 hypothyroidism Diseases 0.000 claims description 2
- 230000002989 hypothyroidism Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 2
- 239000006014 omega-3 oil Substances 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000004897 n-terminal region Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584637P | 2017-11-10 | 2017-11-10 | |
| US62/584,637 | 2017-11-10 | ||
| PCT/US2018/059734 WO2019094533A1 (en) | 2017-11-10 | 2018-11-08 | Angptl8-binding agents and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502065A JP2021502065A (ja) | 2021-01-28 |
| JP2021502065A5 true JP2021502065A5 (enExample) | 2022-01-06 |
| JP7291694B2 JP7291694B2 (ja) | 2023-06-15 |
Family
ID=66439014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524144A Active JP7291694B2 (ja) | 2017-11-10 | 2018-11-08 | Ａｎｇｐｔｌ８結合薬及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10774139B2 (enExample) |
| EP (1) | EP3749691A4 (enExample) |
| JP (1) | JP7291694B2 (enExample) |
| CN (1) | CN111315775A (enExample) |
| AU (1) | AU2018366122A1 (enExample) |
| CA (1) | CA3080148A1 (enExample) |
| WO (1) | WO2019094533A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6680758B2 (ja) | 2014-10-03 | 2020-04-15 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 |
| US10774139B2 (en) | 2017-11-10 | 2020-09-15 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
| WO2019126194A1 (en) * | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| CN110694067A (zh) * | 2019-11-06 | 2020-01-17 | 首都医科大学附属北京安贞医院 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN119367545B (zh) * | 2025-01-02 | 2025-04-08 | 山东第一医科大学(山东省医学科学院) | 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100991A1 (en) | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| AU2012267492A1 (en) | 2011-06-10 | 2014-01-09 | President And Fellows Of Harvard College | Modulation of pancreatic beta cell proliferation |
| CN103764673A (zh) | 2011-06-10 | 2014-04-30 | 北京韩美药品有限公司 | 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用 |
| US10259863B2 (en) | 2013-01-11 | 2019-04-16 | The California Institute For Biomedical Research | Bovine fusion antibodies |
| US8877202B2 (en) * | 2013-02-07 | 2014-11-04 | Immunomedics, Inc. | Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| ES2960807T3 (es) | 2013-10-11 | 2024-03-06 | Us Health | Anticuerpos contra TEM8 y su uso |
| JP6680758B2 (ja) | 2014-10-03 | 2020-04-15 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 |
| AR100680A1 (es) * | 2015-01-26 | 2016-10-26 | Macrogenics Inc | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| MX386832B (es) * | 2016-04-08 | 2025-03-19 | Regeneron Pharma | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. |
| AU2017363143B2 (en) | 2016-11-17 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity with anti-ANGPTL8 antibodies |
| US10774139B2 (en) | 2017-11-10 | 2020-09-15 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
-
2018
- 2018-11-08 US US16/184,548 patent/US10774139B2/en not_active Expired - Fee Related
- 2018-11-08 AU AU2018366122A patent/AU2018366122A1/en not_active Abandoned
- 2018-11-08 CN CN201880070810.0A patent/CN111315775A/zh active Pending
- 2018-11-08 CA CA3080148A patent/CA3080148A1/en active Pending
- 2018-11-08 WO PCT/US2018/059734 patent/WO2019094533A1/en not_active Ceased
- 2018-11-08 EP EP18877271.9A patent/EP3749691A4/en not_active Withdrawn
- 2018-11-08 JP JP2020524144A patent/JP7291694B2/ja active Active
-
2020
- 2020-08-18 US US16/996,623 patent/US11566067B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502065A5 (enExample) | ||
| JP2025179073A (ja) | 二重特異性抗体 | |
| JP2024150751A5 (enExample) | ||
| JP2020152735A5 (enExample) | ||
| JP2022101693A5 (enExample) | ||
| JP2020002172A5 (enExample) | ||
| JP2020099324A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| IL268745A (en) | Antibody drug conjugates (adc) that bind to 158p1d7 proteins | |
| JP2009525764A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| TW201041592A (en) | Anti-TNF-α antibodies and their uses | |
| JP2016538318A5 (enExample) | ||
| JP2016536020A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2016520520A5 (enExample) | ||
| CN106573983B (zh) | 用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段 | |
| JP2021508707A5 (enExample) | ||
| JP2010527939A5 (enExample) |